Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 10, Octobre 2003
Page(s) 943 - 949
Section M/S Revues
Publié en ligne 15 octobre 2003
  1. Poirier P, Eckel RH. The heart and obesity. In: Fuster V, Alexander RW, King S, O’Rourke RA, Roberts R, Wellens HJJ, eds. Hurst’s the heart, 10e ed. New York: McGraw-Hill Companies, 2000: 2289–303.
  2. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97: 2099–100.
  3. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. Int J Obes Relat Metab Disord 2002; 26: 425–36.
  4. Poirier P, Després JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 2003; 23: 161–9.
  5. Després JP. Health consequences of visceral obesity. Ann Med 2001; 33: 534–41.
  6. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486–97.
  7. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 1984; 288: 1401–4
  8. Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993; 269: 483–7.
  9. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843–8.
  10. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men ? Circulation 2000; 102: 179–84.
  11. Pascot A, Lemieux I, Prud’homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007–14.
  12. Lemieux S, Després JP. Metabolic complications of visceral obesity: contribution to the aetiology of type 2 diabetes and implications for prevention and treatment. Diabetes Metab 1994; 20: 375–93.
  13. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601–10.
  14. Hashimoto M, Akishita M, Eto M, et al. The impairment of flowmediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord 1998; 22: 477–84.
  15. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105: 2696–98.
  16. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45: 391–418.
  17. Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001; 154: 497–504.
  18. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with longstanding stable angina. Circulation 2001; 103: 3062–8.
  19. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.
  20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.
  21. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year followup results of the Helsinki policemen study. Circulation 1998; 98: 398–404.
  22. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–7.
  23. McGill HC. Fatty streaks in the coronary arteries and aorta. Lab Invest 1968; 18: 560–4.
  24. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750–4.
  25. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000; 72: 1307S–15S.
  26. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA 1953; 152: 1090–3.
  27. McGill HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological determinants of atherosclerosis in youth (PDAY) research group. Arterioscler Thromb Vasc Biol 1995; 15: 431–40.
  28. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002; 21: 213–7.
  29. McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105: 2712–18.
  30. McGill HC, McMahan CA, Zieske et al. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000; 102: 374–9.
  31. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968–77.
  32. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977; 39: 452–8.
  33. Otsuka Y, Miyazaki S, Okumura H, et al. Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balloon coronary angioplasty. Eur Heart J 2000; 21: 1790–96.
  34. Korpilahti K, Syvanne M, Engblom E, Hamalainen H, Puukka P, Ronnemaa T. Components of the insulin resistance syndrome are associated with progression of atherosclerosis in nongrafted arteries 5 years after coronary artery bypass surgery. Eur Heart J 1998; 19: 711–9.
  35. Eisenstein EL, Shaw LK, Nelson CL, Anstrom KJ, Hakim Z, Mark DB. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. Obes Res 2002; 10: 83–91.
  36. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox ? J Am Coll Cardiol 2002; 39: 578–84.
  37. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291–7.
  38. Poirier P, Després JP. Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459–70.
  39. Knowler WC, Barrett-Connor E, Fowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
  40. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.